Alpha Lipoic Acid

ALA is one of the most clinically studied natural compounds in the world, with nearly 30 systematic reviews and meta-analyses published on its benefits (PMC12191796). Here's what the research shows across the key areas:

Nerve Support: The landmark ALADIN trial — a double-blind, placebo-controlled study of 328 patients — found that 600mg of ALA daily significantly reduced pain, burning, tingling, and numbness (PMID: 9285502). A separate systematic review of five RCTs found that 600mg per day resulted in a 50% reduction in total neuropathy symptoms (PMID: 20421656). A further meta-analysis of four high-quality trials gave ALA a Grade A recommendation for neuropathic pain relief (PMC3272801). The SYDNEY 2 trial confirmed that 600mg oral daily is the optimal dose (PMID: 17065669). German doctors have prescribed it for this purpose since 1966.

Blood Sugar: A meta-analysis of 24 RCTs found that ALA supplementation significantly decreased fasting glucose, HbA1c, insulin resistance, triglycerides, total cholesterol, and LDL cholesterol (PMID: 29990473). A separate clinical study showed 600mg daily improved insulin sensitivity by 25% after just 4 weeks (PMC2657658).

Inflammation: A meta-analysis of 41 RCTs found that ALA produced significant reductions in three major inflammatory markers: TNF-α, IL-6, and C-reactive protein (PMID: 31221283).

Brain Protection: ALA is one of the few antioxidants that crosses the blood-brain barrier (PMID: 8958163). A 12-month randomized placebo-controlled trial of Alzheimer's patients found that those taking 600mg ALA showed less cognitive and functional decline compared to placebo (PMC3886557).

Cellular Energy: ALA is a mandatory cofactor in the two mitochondrial enzyme complexes responsible for converting glucose into usable energy (PMID: 11467343). Research confirms that the body's natural production declines with age — and food sources deliver only 1–3mg, far below the 300–600mg clinical threshold (PMC2657658).

Antioxidant Network: ALA simultaneously regenerates Vitamins C, E, and glutathione — which is why researchers call it the "network antioxidant" (StatPearls NBK564301). It also stimulates glutathione production in tissues that oral glutathione itself cannot reach (PMID: 8958163)

Yes. The SYDNEY 2 trial — a multicenter, double-blind, placebo-controlled study that tested three different doses — concluded that 600mg once daily provides the optimal risk-to-benefit ratio. Lower doses found in most competitor products (150–300mg) fall below the threshold shown to produce meaningful results in clinical research.

Every clinical trial that proved ALA works — ALADIN, SYDNEY, NATHAN 1 — tested ALA by itself at 600mg. Not a 12-ingredient complex. When multiple compounds are packed into one capsule, they compete for the same absorption pathways in your gut. Nutrissa contains one ingredient, so the full 600mg reaches your cells without competing with anything else.

ALA has been a prescription drug in Germany since 1966 — backed by 15+ randomized controlled trials. The reason most American doctors don't recommend it is structural: natural compounds can't be patented, so no pharmaceutical company will fund the $1–2 billion FDA approval process. The compound works. The business model to bring it through US regulatory approval doesn't exist.

Some customers report noticeable improvements within the first 1–2 weeks — particularly with energy and sleep quality. For nerve comfort and blood sugar support, the more typical timeframe is 4–8 weeks of consistent daily use. This is why we recommend starting with at least a 3-month supply to give your body the full window it needs.